Kornimate/medical-research-clean huggingface dataset:
human papilloma virus (hpv) circulating tumor dna (ctdna) in cervical cancer

Conditions: Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Infiltrating Cervical Carcinoma; Metastatic Cervical Carcinoma; Recurrent Cervical Carcinoma; Stage I Cervical Cancer FIGO 2018; Stage IA Cervical Cancer FIGO 2018; Stage IA1 Cervical Cancer FIGO 2018; Stage IA2 Cervical Cancer FIGO 2018; Stage IB Cervical Cancer FIGO 2018; Stage IB1 Cervical Cancer AJCC v8; Stage IB2 Cervical Cancer FIGO 2018; Stage IB3 Cervical Cancer FIGO 2018; Stage II Cervical Cancer FIGO 2018; Stage IIA Cervical Cancer FIGO 2018; Stage IIA1 Cervical Cancer FIGO 2018; Stage IIA2 Cervical Cancer FIGO 2018; Stage IIB Cervical Cancer FIGO 2018; Stage III Cervical Cancer FIGO 2018; Stage IIIA Cervical Cancer FIGO 2018; Stage IIIB Cervical Cancer FIGO 2018; Stage IIIC Cervical Cancer FIGO 2018; Stage IIIC1 Cervical Cancer FIGO 2018; Stage IIIC2 Cervical Cancer FIGO 2018; Stage IV Cervical Cancer FIGO 2018; Stage IVA Cervical Cancer FIGO 2018; Stage IVB Cervical Cancer FIGO 2018

Summary: this study collects blood samples to determine if the dna of hpv that causes cervical cancer can be detected in patients with cervical cancer that is new (primary), has come back (recurrent), or has spread to other places in the body (metastatic) and are undergoing treatment with surgery, radiotherapy, chemotherapy, and/or immunotherapy. researchers may use this information to predict response (good or bad) of the cervical cancer to treatment and detect recurrent cancer sooner.


Eligibility criteria:
inclusion criteria: * able to provide written consent * patient has given permission to give tumor/blood sample for research testing * histological confirmation of adenocarcinoma, adenosquamous, or small cell carcinoma of the cervix * known hpv status defined as positive staining for p16 on ihc or dna ish for hpv * willingness to return to enrolling institution (mayo clinic rochester or the university of minnesota) for follow-up (during the active monitoring phase of the study) or complete blood draws locally using study mail-in kits * consent to allow blood specimens to be shared with mayo clinic study personnel and potential external collaborators for sample analysis * definitive chemoradiotherapy for locally advanced disease (figo stage ib2-iiic) * figo 2019 stage ib2-iiic or not a surgical candidate * plan to undergo definitive chemoradiotherapy including external beam radiotherapy, brachytherapy, and chemotherapy exclusion criteria: * other active malignancy =\< 2 years prior to registration. * exceptions: non-melanotic skin cancer * note: if there is a history or prior malignancy, they must not be receiving other specific treatment for cancer * pregnancy or lactation * inability on the part of the patient to understand the informed consent to be compliant with the protocol
effect of whole-body vibration on plasma sclerostin level

Conditions: Osteopenia

Summary: the aim of this study is to investigate effect of whole-body vibration on plasma sclerostin level in healthy young adult women. fifteen healthy young adult women are planned to include in this study. all cases will be trained on a whole-body vibration (wbv) platform (power plate) 5 times a week for one week period. training duration will be short at the beginning but progressed slowly. the amplitude of vibration will be 2 mm and the frequency of the vibration will be 40 hz. the subjects will be asked to report negative side effects or adverse reactions in their training diary. previbration and postvibration (just after, 10.minute and 30.minute) levels of plasma sclerostin will be measured on first, second and fifth day of experiment. sclerostin levels will be measured by human sclerostin elisa kit.

whole-body vibration has a strong osteogenic effect. the cyclic mechanical loading to the bone stimulates the osteocytes. sclerostin, the protein product of the sost gene, is an osteocyte-specific cysteine knot-secreted glycoprotein that is a potent inhibitor of bone formation. sost/sclerostin levels have been reported to be reduced by mechanical stimulation. the aim of this study is to investigate effect of whole-body vibration on plasma sclerostin level in healthy young adult women.

Eligibility criteria:
inclusion criteria: * healthy women, * women with ages varying between 20 and 40 years * right-handed women exclusion criteria: * lower extremity problems 1. orthopedic problems: shortness of legs, congenital anomalies, etc. 2. joint disease (arthritis, joint prosthesis, etc.) 3. other painful pathologies in the lower extremities (fractures, tendinitis,bursitis, etc.) 4. circulation problems in the lower extremities * dorsolumbar diseases: vertebral fract, disc hernias, spondylodiskitis, etc. * systemic disease cases 1. systemic bone disease: osteoporosis, osteomalacia, paget's disease 2. hypertension (\>135 mmhg systolic, \>85 mmhg diastolic) 3. heart dis.(coronary dis, conduction/rhythm prob, cardiac pacemaker) 4. infectious diseases 5. endocrine diseases (diabetes mellitus etc) * neurological diseases (cns problems, peripheral neuropathy) * menstrual cycle disorders, amenorrhea, lactation, oral contraceptive use * cases during the ovulatory period (11-16th day of menses) * obesity (bmi \>30 kg/m2) or low bmi (bmi \<20 kg/m2) * vertigo * cognitive function disorders * women whose blood samples were not taken in the time planned * women whose blood samples hemolyzed

Keywords: sclerostin whole-body vibration
implantable phakic lens (ipcl) vs implantable collamer lens

Conditions: Myopia

Summary: phakic intraocular lenses (piol) of different designs and materials have been used effectively instead of corneal refractive surgery in certain situations. the piol exhibits a number of advantages over corneal techniques as it is suitable for high myopes, with lower production of aberrations, and superior contrast sensitivity. keeping the accommodation is its definite lead over refractive lens exchange. the visian implantable collamer lens (icl; staar surgical, monrovia, ca), a posterior chamber piol, has been stated to be useful for the correction of high myopia. nevertheless, as an intraocular procedure, it is associated with a risk of complications as probable injury to anterior segment, retinal detachment and endophthalmitis. the implantable phakic contact lens (ipcl v2, caregroup sight solutions, india) has been developed as an alternative for the icl, at a noticeable financial advantage. furthermore, the highestmyopic correction which is instantly accessible with icl is -18.0 d. meanwhile, ipcl can provide correction higher degrees up to -30.0 d. former researches have been made to assess the safety and efficiency of icl implantation, to evaluate various devices for anterior segment imaging postoperatively and to identify changes in anterior segment after surgery. a recent study determined the safety of the ipcl over a minimum follow-up period of one year. in this work the investigators aimed to compare the refractive results and the adverse effects of the ipcl and the icl in treatment of myopia in adults.


Eligibility criteria:
inclusion criteria: * myopia of more than 6 diopter * central anterior chamber depth more than 2.8 mm exclusion criteria: * unstable refraction * any other ocular disease * any systemic disease
an adequate cost effective follow up protocol for bone & soft tissue sarcomas - a prospective randomized trial

Conditions: Sarcoma

Summary: the purpose of this study is to evaluate the impact on overall survival of an intensive follow-up protocol (as practiced today at tmh) against a more cost effective follow-up protocol in patients operated for extremity sarcoma.

follow up studies are performed for a variety of reasons. the detection of a recurrence of the index lesion is the foundation of surveillance. detection of other medical conditions is a secondary benefit. psychologically, follow up testing can serve as a source of reassurance. whether an increased frequency of follow up and the use of various expensive imaging modalities for screening and early detection of recurrence actually results in improving overall survival of patients with extremity sarcomas is a question that remains as yet unanswered. currently followed post -operative surveillance regimes are empirical and vary widely from centre to centre. allocation of limited health funding should be guided by evidence based recommendations rather than empirical beliefs. an ideal surveillance regime should meet the criteria of easy implementation, accuracy and cost effectiveness. in a vast country like india where patients often travel thousands of kilometers in their search for quality medical care the frequency of routine follow up visits is as important as studying the role of expensive screening modalities while drawing up guidelines for cost effective follow up strategies. this study, a prospective randomized controlled trial, attempts to outline guidelines regarding the role of follow up vis a vis frequency and the use of various imaging modalities for early detection of recurrence in improving overall survival of patients with extremity sarcomas.

Eligibility criteria:
inclusion criteria: 1. patients operated for primary or recurrent extremity bone \& soft tissue sarcomas.(both limb salvage and amputations) 2. non metastatic at presentation. 3. patients reliable for follow-up. exclusion criteria: 1. non-extremity sarcomas. 2. metastatic at presentation 3. patients unreliable for follow up.

Keywords: bone tumor soft tissue tumor
study to evaluate d-1553 in subjects with solid tumors

Conditions: Solid Tumor, Adult; NSCLC; CRC

Summary: this is a phase 1/2, open label study of d-1553 single agent and combination treatment to assess the safety and tolerability, identify the mtd and rp2d, evaluate the pk properties and antitumor activities in subjects with advanced or metastatic solid tumor with krasg12c mutation.


Eligibility criteria:
inclusion criteria * subject with histologically proven, locally advanced, unresectable and/or metastatic solid tumor, for which no standard treatment is available, or the subject is refractory to or intolerant of existing standard treatment. * subject has krasg12c mutation in tumor tissue or other bio-specimens containing cancer cells or dna. historical, local laboratory result (up to 5 years prior to this study) can be used for phase 1 subjects. phase 2 subjects must be tested for krasg12c mutation by a central laboratory. * subject has tumor type requirement as follows: advanced or metastatic solid tumors including nsclc and crc. * subject has measurable disease according to recist, v1.1. exclusion criteria: * subject with unstable or progressive central nervous system (cns) metastases. * subject with acute myocardial infarction, severe/unstable angina; or with cardiac insufficiency of new york heart association functional classification grade 2 or above. * subject has corrected qt interval using fridericia's formula (qtcf) prolongation at rest, where the mean qtc interval is \> 480 msec based on triplicate measurements of electrocardiogram (ecg). * subject with stroke or other severe cerebrovascular diseases within 12 months before enrollment; * subject with interstitial lung disease or acute lung infection not yet recovered including but not limited to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection; * subject has any history or evidence of substance abuse or medical, psychological or social conditions that may, in the opinion of the investigator, interfere with participation in the study or evaluation of the study results. * subject has impaired gastrointestinal (gi) function or gi diseases that may significantly alter the absorption or metabolism of oral medications. * subject has unresolved toxicities from prior anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to nci ctcae, v5.0, grade ≤ 1 (grade ≤ 2 for peripheral neuropathy). * subject had major surgery within 4 weeks prior to study intervention administration or last dose of palliative radiation therapy within 2 weeks prior to study intervention administration. * subject is pregnant or lactating.
survey examining the frequency and severity of acid related symptoms while taking nexium

Conditions: Gastric Acid Suppression; Proton Pump Inhibitors

Summary: this study will assess the effectiveness of nexium at alleviating upper gi symptoms in subjects and evaluate with which treatment regimen and on which indications acid suppression with isomeric proton pump inhibitor is used in routine clinical practice in albania.


Eligibility criteria:
inclusion criteria: * subject must have had upper gi symptoms requiring acid suppression treatment * treatment with nexium is in accordance with indications and dosing approved in albania. * start of treatment at least 2 weeks prior to enrollment to this study 5. written informed consent is signed. exclusion criteria: * known hypersensitivity to nexium or any other constituents of the formulation * concomitant administration of atazanavir and nelfinavir. * alarming upper gi symptoms (i.e. significant unintended weight loss, vomiting, dysphasia, hematemesis, melena, fever, jaundice or any other sign indicating serious or malignant disease

Keywords: gerd gastric and duodenal ulcers nsaid therapy
therapeutic effects of constraint-induced movement therapy on young children with cerebral palsy

Conditions: Cerebral Palsy Spastic Hemiplegic

Summary: this study evaluates the therapeutic effects of constraint-induced movement therapy on infants and children with hemiplegic cerebral palsy. half of the participants will receive cimt (constraint-induced movement therapy) and others will not.

this study evaluates the therapeutic effects of constraint-induced movement therapy on infants and children with hemiplegic cerebral palsy. half of the participants will receive cimt (constraint-induced movement therapy) and others will not. participants will be randomly assigned to either cimt group or control group. children of the cimt group will wear forearm splint 24 hours for 3 weeks to inhibit use of the unaffected arm.

Eligibility criteria:
inclusion criteria: * spastic hemiplegic cerebral palsy patients * 7\~36 months old exclusion criteria: * cognitive impairment severe enough to make participation impossible * uncontrolled epilepsy * visual or hearing impairment * musculoskeletal disorders

Keywords: constraint-induced movement therapy hemiplegia hand function gross motor
reversing synchronized brain circuits with targeted auditory-somatosensory stimulation to treat phantom percepts

Conditions: Tinnitus

Summary: the goal of the study is to reduce tinnitus (ringing in the ear) loudness and improve the quality of life for those that are affected by tinnitus. this study will enroll subjects who have constant and bothersome tinnitus with no greater than a mild hearing loss up to 6 khz, and no greater than a moderate hearing loss in the tinnitus frequencies. subjects must also have the ability to alter the loudness or pitch of the ringing in their ears by performing a head, neck, face, or upper body movement. subjects will be given both the treatment and sham arms (the study will randomly assign which arm is administered first) and will have a washout period of 6 weeks after each arm. the study will take approximately 36 weeks for subjects to complete and will enroll up to 300 individuals.


Eligibility criteria:
inclusion criteria: * must report constant, subjective, preferably unilateral tinnitus without any active external or middle ear pathology. * no greater than a mild hearing loss up to 6 khz, and no greater than a moderate hearing loss at the tinnitus frequencies. * must be able to modulate their tinnitus with a somatic maneuver * preferably onset of tinnitus less than one year ago, but present for at least 6 months. tinnitus should be bothersome. * absence of retrocochlear pathology/8th nerve lesion * no participation in a tinnitus treatment regimen within the past six months or participation in the university of michigan stage 1 clinical trial. exclusion criteria: * diagnosis of meniere's disease * diagnosis of semicircular canal dehiscence * unilateral or bilateral cochlear implant recipients * diagnosis of acoustic neuroma * evidence of retrocochlear disease * certain medications and conditions (will be reviewed at screening)

Keywords: tinnitus ringing in the ear
bone mineral density, disease duration, and activity in ankylosing spondylitis

Conditions: Ankylosing Spondylitis; Osteoporosis; BMD

Summary: our clinical study aimed to evaluate the prevalence of osteoporosis (op) in patients with ankylosing spondylitis (as) and to investigate the relationship between clinical, disease activity, physical function and disease duration, and bone mineral density (bmd).

in this cross-sectional study, patients who were admitted to the rheumatology clinic between 18 and 65 years of age and diagnosed as as according to the modified new york diagnostic criteria were included patients group was divided two part as patients with (group 1)and without (group 2) osteoporosis. the patient's global rating scale is a self-assessed scale of the patient with a grade of 10 (1: very bad, 5: moderate, 10: very good). to assess the disease activity, bath ankylosing spondylitis disease index (basdai) and bath ankylosing spondylitis functional index (basfi) were evaluated. basdai is a self-assessment scale used to determine disease activity in patients with as. schober measurement was used to evaluate lumbar mobility of the patients. chest expansions were measured in all patients. body mass index (bmi) was calculated as kg/height m2. erythrocyte sedimentation rate (esh mm / h), c-reactive protein (crp mg / l) levels were measured in all patients. bmd measurements were made by using dual-energy x-ray absorptiometry (dexa) and lumbar vertebra (l1-4) and left femur (femoral neck and total) regions. dexa measurements (ge / lunar dpx pro) were performed and the results were recorded using standard t score. bone mineral densities of patients were based on the world health organization (who) classification of a t score between -1 and -2.5 for osteopenia; and a score of -2.5 for osteoporosis.

Eligibility criteria:
inclusion criteria: * patients diagnosed as as according to the modified new york diagnostic criteria were included exclusion criteria: * patients previously diagnosed with op, * patients previously treated with op, * patients with bone fractures previously associated with op, * those using drugs that affect bone metabolism, metabolic bone diseases (paget's -disease, osteomalacia, hyperparathyroidism), * diabetes mellitus, * hypothyroidism, hyperthyroidism, * patients with kidney, liver and intestinal diseases, * those using corticosteroids
study of gemcitabine, irinotecan and panitumumab in patients with advanced and metastatic biliary tract adenocarcinoma

Conditions: Biliary Cancer; Cholangiocarcinoma

Summary: this study evaluates the combination chemotherapy with gemcitabine, irinotecan and panitumumab in patients with advanced biliary cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed local advanced unresectable/metastatic adenocarcinoma of biliary tract * measurable disease * available tumor tissue for investigational immunohistochemical evaluations * ecog ps 0-2 * no prior chemotherapy, biologic therapy or radiation therapy * age eighteen and older * lab values per protocol exclusion criteria: * life expectancy less than three months * concurrent use of chemotherapy not indicated in the study protocol or any other investigational agents and patients who have received investigational drugs less than four weeks prior to enrollment * prior therapy, which affects or targets the egf pathway * treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer * recovery from major surgery within three weeks of the start of study treatment

Keywords: biliary cancer cholangiocarcinoma panitumumab
home test for measuring plasma p-tau217 in alzheimer's disease

Conditions: Alzheimer Disease; Healthy Subjects

Summary: the goal of this is to develop an easy at home test that can be used to assist in diagnosing alzheimer's disease (ad). the test will use an fda approved device for at home blood sample collection. the blood samples will be evaluated to determine if the concentration of p-tau217, a biomarker that is elevated in ad patients, measured from blood samples collected using the at home device is comparable to the results obtained from blood samples collected by venipuncture.


Eligibility criteria:
inclusion criteria: * subject with alzheimer's disease only: diagnosed according the nia-aa diagnostic ad criteria * healthy control only: subject does not have history of cognitive impairment * 55 - 90 years old * subject able to comply with study procedures * subjects must be able to use the tasso device for blood sample collection as per the provided instructions (can be performed with the assistance of a caregiver) * subjects must be able to undergo iv sampling * have a study partner who will provide written informed consent to participate, and assist with blood collection when applicable exclusion criteria: * subjects with systemic conditions which were not adequately controlled through a stable medication regimen * subjects with any known significant bleeding disorders or conditions that contraindicate blood sample collection (e.g., hemophilia, severe thrombocytopenia) * subjects with a known history of severe skin allergies or reactions to adhesives (since the tasso device involves adhesive application to the skin) * subjects currently taking anticoagulant or antiplatelet medications that could interfere with blood collection or increase the risk of complications * subjects who have undergone major surgery or have been hospitalized for any reason in the last 3 months prior to study enrollment * participation in a clinical study within the 2 month
prospective evaluation of hypofractionated stereotactic rt using cyberknife for patients with prostate cancer

Conditions: Prostate Cancer

Summary: the main purpose of study is to evaluate hypofractionated stereotactic radiotherapy (sbrt) using cyberknife for patients with low and intermediate risk of progression prostate cancer.

evaluation of the usefulness expression of selected proteins (pten, smad4, cyclin d1, spp1) as prognostic and predictive factors.

Eligibility criteria:
inclusion criteria: * men from 40 to 75 years of age with a confirmed adenocarcinoma prostate, prostate biopsy will be performed \<180 days prior to the randomization date, * completed assessment of tumor differentiation according to gleason grading allows to perform stratification; * general performance status according to the eastern cooperative oncology group (ecog) classification ( 0 -1), * belonging to the group of low and intermedium risk of progression; (ct1-ct2c, gleason 7, psa to 19.9 ng / ml), ct specified by ajcc 7 edition (appendix 2), * psa marked at least 10 days after or before the biopsy, and for patients taking phytosterol 30 days after discontinuation, * no distant metastases, * signing informed consent, * morphological and biochemical blood parameters within the normal limits. exclusion criteria: * the presence of active cancer, except skin cancer preceding period 5 years prior to randomization, * surgical treatment (radical prostatectomy) or rt in the pelvic area, * co-morbidities that may significantly affect the expectancy life of the patients * do not meet the criteria for inclusion.

Keywords: prostate cancer, sbrt, ultrafractionation, cyberknife